OS Therapies IncorporatedOSTXNYSE
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+36.2%
5Y CAGR+573.0%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+36.2%/yr
Annual compound
5Y CAGR
+573.0%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
13804.8x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$8.31M+192.9%
2024$2.84M-11.8%
2023$3.22M-2.3%
2022$3.29M+51.4%
2021$2.17M+361193.1%
2020$601.78-